Results 31 to 40 of about 2,295,331 (380)

Computational Models for Transplant Biomarker Discovery. [PDF]

, 2015
Translational medicine offers a rich promise for improved diagnostics and drug discovery for biomedical research in the field of transplantation, where continued unmet diagnostic and therapeutic needs persist.
Sarwal, Minnie M, Wang, Anyou
core   +2 more sources

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Annals of Oncology, 2018
Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) can result in impressive ...
T. Chan, M. Yarchoan, E. Jaffee, C. Swanton, S. Quezada, A. Stenzinger, Solange Peters   +6 more
semanticscholar   +1 more source

Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy

Biomarker Research, 2022
The claudin18.2 (CLDN18.2) protein, an isoform of claudin18, a member of the tight junction protein family, is a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of ...
Weijie Cao, H. Xing, Yingmei Li, Wenliang Tian, Yongping Song, Zhongxing Jiang, Jifeng Yu   +6 more
semanticscholar   +1 more source

A Bayesian adaptive marker‐stratified design for molecularly targeted agents with customized hierarchical modeling [PDF]

, 2019
It is well known that the treatment effect of a molecularly targeted agent (MTA) may vary dramatically, depending on each patient's biomarker profile. Therefore, for a clinical trial evaluating MTA, it is more reasonable to evaluate its treatment effect ...
Cao, Sha, Guo, Beibei, Han, Yan, Zang, Yong, Zhang, Chi   +4 more
core   +2 more sources

Gene expression profiling of immunomagnetically separated cells directly from stabilized whole blood for multicenter clinical trials

Clinical and Translational Medicine, 2014
Background Clinically useful biomarkers for patient stratification and monitoring of disease progression and drug response are in big demand in drug development and for addressing potential safety concerns.
Martin Letzkus, Evert Luesink, Sandrine Starck‐Schwertz, Marc Bigaud, Fareed Mirza, Nicole Hartmann, Bernhard Gerstmayer, Uwe Janssen, Andreas Scherer, Martin M Schumacher, Aurelie Verles, Alessandra Vitaliti, Nanguneri Nirmala, Keith J Johnson, Frank Staedtler   +14 more
doaj   +1 more source

Proteome Profiling of Diabetic Mellitus Patient Urine for Discovery of Biomarkers by Comprehensive MS-Based Proteomics

Proteomes, 2018
Diabetic mellitus (DM) is a disease that affects glucose homeostasis and causes complications, such as diabetic nephropathy (DN). For early diagnosis of DN, microalbuminuria is currently one of the most frequently used biomarkers.
Yoshitoshi Hirao, Suguru Saito, Hidehiko Fujinaka, Shigeru Miyazaki, Bo Xu, Ali F. Quadery, Amr Elguoshy, Keiko Yamamoto, Tadashi Yamamoto   +8 more
doaj   +1 more source

Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program [PDF]

, 2017
Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's ...
Albin, Roger, Alcalay, Roy N., Babcock, Debra, Bowman, F. DuBois, Chen-Plotkin, Alice, David, Karen K., Dawson, Ted M., Dewey, Richard B., Jr., Foroud, Tatiana, German, Dwight, Gwinn, Katrina, Huang, Xuemei, Lungu, Codrin, Petyuk, Vlad, Potashkin, Judith A., Rosenthal, Liana S., Saunders-Pullman, Rachel, Scherzer, Clemens R., Sieber, Beth-Anne, St Hillaire-Clarke, Coryse, Sutherland, Margaret, Swanson-Fischer, Christine, Vaillancourt, David E., Walt, David R., West, Andrew B., Zhang, Jing   +25 more
core   +1 more source

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

Nucleic Acids Res., 2012
Alterations in cancer genomes strongly influence clinical responses to treatment and in many instances are potent biomarkers for response to drugs. The Genomics of Drug Sensitivity in Cancer (GDSC) database (www.cancerRxgene.org) is the largest public ...
Wanjuan Yang, Jorge Soares, Patricia Greninger, E. Edelman, H. Lightfoot, S. Forbes, Nidhi Bindal, D. Beare, James A. Smith, I. R. Thompson, Sridhar Ramaswamy, P. Futreal, D. Haber, M. Stratton, C. Benes, U. McDermott, M. Garnett   +16 more
semanticscholar   +1 more source

Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.

Cancer Discovery, 2020
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, varies across malignancies. Panel sequencing-based estimates of TMB have largely replaced whole-exome sequencing-derived TMB in the ...
D. Sha, Zhaohui Jin, J. Budczies, K. Kluck, A. Stenzinger, F. Sinicrope   +5 more
semanticscholar   +1 more source

How shall we use the proteomics toolbox for biomarker discovery? [PDF]

, 2007
Biomarker discovery for clinical purposes is one of the major areas in which proteomics is used. However, despite considerable effort, the successes have been relatively scarce.
Hochstrasser, Denis, Lescuyer, Pierre, Rabilloud, Thierry   +2 more
core   +5 more sources